Fleetwood: stumbling but standing
Persistent losses from the RV business mask strong cash flow from the manufacturing business. The case for an asset sale is slowly building.
Fleetwood: stumbling but standing
Persistent losses from the RV business mask strong cash flow from the manufacturing business. The case for an asset sale is slowly building.
Gentrack downgraded
It was a regrettably short lived buying opportunity, but with this software maker up 36% since our initial Buy rec, it's time for a downgrade.
Sonic hit by government cuts
Sonic Healthcare's share price has been hit by proposed cuts to Medicare's pathology budget.
Hansen increases earnings outlook
Hansen Technologies has upgraded its earnings guidance after a better than expected half.
Mirvac and Stockland's understated risk
With evidence that house price growth is slowing, these two listed property trusts are more exposed than many investors think.
Veda takeover progresses
Equifax's bid for Veda Group looks likely to succeed. Look out for your documentation shortly.
Qantas profit set to soar
The airline's recovery seems to be taking root, but Qantas isn't out of the woods yet.
iCar Asia's share price fall
Volatile stocks are par for the course at this end of the market. The recent decline provides us with another opportunity.
Resources sector price falls
Commodity price falls have caused further carnage in the resources sector, but we're happy with our recommendations.
DEXUS to purchase Investa Office Fund
Dexus has offered an 7% premium to NTA for the Investa Office Fund, no doubt encouraged by the 15% premium on its own stock.
Will Theranos destroy Sonic Healthcare?
A high-tech startup threatens the once calm pathology industry. Will Sonic survive?
Wesfarmers counts on Chaney
Coles and coal are driving Wesfarmers' share price lower but the return of a familiar face is reassuring news.
Xero's North American gamble
Cloud accounting services provider Xero is trying to turn blue sky into reality by taking on the industry leader on its own turf.
Monash IVF now a hold
Monash IVF's share price has risen 33% since its annual result and it's time for a downgrade.
Adding a fresh coat to Dulux
We take a look at this owner of some of Australia's most trusted brands.
Gentrack: the captor, the spoils
Gentrack's moat is widening and the software maker is so busy it's turning business away. But growth comes at a price.
Is Rio Tinto a steel?
Rio Tinto has some of the best mining assets in the world and its shares have been getting cheaper. Is now the time to pile in?
Is Rio Tinto a steel?
Rio Tinto has some of the best mining assets in the world and its shares have been getting cheaper. Is now the time to pile in?
Myer downgraded
Unfortunately the buying opportunity in Myer lasted less than a month and, as we're reluctant to chase the stock, we're downgrading a notch.
Myer downgraded
Unfortunately the buying opportunity in Myer lasted less than a month and, as we're reluctant to chase the stock, we're downgrading a notch.
Seek: AGM 2015
Seek's share price has performed well since our upgrade only two months ago. A little bit of good news has gone a long way.
F&P Healthcare: Interim result 2016
This maker of sleep apnea masks and flow generators consistently beats our expectations and it's time to revisit the price guide.
Call 1300 880 160
Start a chat
Schedule a call
